Abstract Disclosure: N. Markovic: None. M. Brankovic: None. A. Palani: None. D. Matassa:
None. Studies have shown that primary aldosteronism (PA) is an underlying cause in up to …

Abstract Disclosure: K. Zekarias: None. K. Tessier: None. J. Kohlenberg: None. Introduction:
The screening rate for primary aldosteronism (PA) is low among people with resistant …

Objective Primary aldosteronism (PA) is the most common secondary cause of hypertension.
Patients with PA experience significant cardiovascular and other complications compared …

Background: Primary aldosteronism is a common cause of treatment-resistant hypertension.
However, evidence from local health systems suggests low rates of testing for primary …

In Reply We appreciate the perspective from Boulestreau and Couffinhal on our recent
initiative to enhance screening for primary aldosteronism (PA) by leveraging electronic …

Clinical practice guidelines recommend screening for primary hyperaldosteronism (PH) in
patients with resistant hypertension. However, screening rates are low in the outpatient …

Introduction: Because hyperaldosteronism is the most common curable reason for
secondary hypertension, screening is recommended. However, prevalence among general …

Primary aldosteronism (PA) is present in up to 20% of patients with treatment‐resistant
hypertension (TRH). Investigation for PA in patients with TRH is recommended by current …

Primary aldosteronism (PA) is a major secondary form of hypertension that is associated
with a disproportionately increased cardiovascular risk beyond blood pressure (BP). 1 The …

Resistant hypertension (RH) is defined as having either (1) a blood pressure (BP) of 130/80
mm Hg or more, despite maximally tolerated doses of 3 or more antihypertensive drugs (with …